Congratulations to EFL Alum, C2i Genomics (CEO Asaf Zviran), on raising a $100M Series B!
C2i Genomics, a Life Sciences alumni of EFL, is developing a platform to detect and monitor tumor lesions in a patient’s standard blood sample, thus enabling rapid treatment decision-making based on real-time information. The technology leverages proprietary mathematical inference models and machine learning techniques, which provide quantification of circulating tumor DNA with 100X higher sensitivity than current methods.
